US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

Pramipexole Dihydrochloride Tablets 0.5 mg

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-198-16 D-1446-2019
Class II · Moderate risk Terminated

Pramipexole Dihydrochloride Tablets 0.25 mg

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-197-10 D-1445-2019
Class II · Moderate risk Terminated

Pramipexole Dihydrochoride Tablets 0.25 mg

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-197-16 D-1444-2019
Class II · Moderate risk Terminated

Pramipexole DihydrochlorideTablets 0.125 mg

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-196-16 D-1443-2019
Class II · Moderate risk Terminated

Pramipexole Dihydrochloride Tablets 0.125 mg

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-196-10 D-1442-2019
Class II · Moderate risk Terminated

Anastrozole Tablets

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-209-10 D-1441-2019
Class II · Moderate risk Terminated

ANASTROZOLE Tablets

Reason CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Zydus Pharmaceuticals USA Inc NDC 68382-209-06 D-1440-2019
Class II · Moderate risk Terminated

Senna

Reason Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported

Geritrex, LLC NDC 54162-007-08 D-1437-2019
Class II · Moderate risk Terminated

Senna

Reason Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported

Geritrex, LLC NDC 53807-556-08 D-1436-2019
Class II · Moderate risk Terminated

Bevacizumab 2.5 mg/0.1 mL

Reason Lack of assurance of sterility

Avella of Deer Valley, Inc. Store 38 NDC 42852-001-27 D-1308-2019
Class II · Moderate risk Terminated

Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx…

Reason CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Heritage Pharmaceuticals, Inc. NDC 23155-644-09 D-1291-2019
Class II · Moderate risk Terminated

Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx…

Reason CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Heritage Pharmaceuticals, Inc. NDC 23155-646-10 D-1290-2019
Class II · Moderate risk Terminated

Losartan Potassium Tablets USP 50 mg 90 film coated tablets…

Reason CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Heritage Pharmaceuticals, Inc. NDC 23155-645-09 D-1289-2019
Class II · Moderate risk Terminated

Losartan Potassium Tablets USP 100 mg 90 film coated tablets…

Reason CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Heritage Pharmaceuticals, Inc. NDC 23155-646-09 D-1288-2019
Class II · Moderate risk Terminated

Losartan Potassium Tablets

Reason CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Heritage Pharmaceuticals, Inc. NDC 23155-645-10 D-1287-2019
Class II · Moderate risk Terminated

Articaine DENTAL

Reason Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the printed carton are labeled appropriately as Articadent DENTAL.

Septodont Inc. NDC 66312-601-16 D-1307-2019
Class II · Moderate risk Terminated

DrKids Children's Cough & Chest Congestion DM

Reason CGMP Deviations: Recall as a precautionary measure due to potential risk of product contamination with the bacteria B. cepacia.

Unipharma, Llc. NDC 70302-013-20 D-1301-2019
Class II · Moderate risk Terminated

CVS Health Children's Allergy Relief Liquid Medication…

Reason CGMP Deviations: Recall as a precautionary measure due to potential risk of product contamination with the bacteria B. cepacia.

Unipharma, Llc. NDC 69842-261-01 D-1300-2019